Compare TXRH & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | FMS |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 109698 |
| Industry | Restaurants | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.5B |
| IPO Year | 2004 | N/A |
| Metric | TXRH | FMS |
|---|---|---|
| Price | $160.55 | $22.68 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 18 | 2 |
| Target Price | ★ $194.22 | $30.00 |
| AVG Volume (30 Days) | ★ 916.7K | 445.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | 1.72% | ★ 2.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $9.28 | $3.83 |
| P/E Ratio | $25.93 | ★ $15.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $156.00 | $20.96 |
| 52 Week High | $199.99 | $30.46 |
| Indicator | TXRH | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 46.62 |
| Support Level | $156.87 | $22.50 |
| Resistance Level | $177.84 | $24.02 |
| Average True Range (ATR) | 3.29 | 0.38 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 29.30 | 22.97 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.